RNA therapeutics can be designed to target genes encoding Ca2+ channels that are altered in HF, such as L-type Ca2+ channels (Cav1.2) [56] ryanodine receptors (RyR2) [57] or Sodium/Ca2+ Exchanger (NCX) [58]. The gene discussed is TLX2; the disease is hydrops fetalis.